LONDON: Uniphar plc, a diversified healthcare services business, headquartered in Ireland, today announces its intention to raise up to €150 million by placing new ordinary shares and to seek admission of all of its ordinary shares to trading on the AIM and Euronext Growth markets of the London Stock Exchange and Euronext Dublin, respectively. [the_ad id=”31605″]Uniphar represents a strong combination of scale, growth and profitability. In 2018, the Group generated revenue of €1.55 billion, gross profit of €159.6 million and EBITDA of €46.3 million on a pro forma basis.
The company intends to use the proceeds from the placing to pay the upfront consideration and related costs to complete the acquisition of Durbin; to execute near term bolt-on acquisition opportunities; to fund additional capital expenditure and working capital for growth of the enlarged Group; to reduce Group net leverage; and pay fees, expenses and commissions relating to the offering.
Ger Rabbette, CEO of Uniphar said: “Uniphar has grown significantly to become a leading diversified healthcare services business, in line with our vision to improve patient access to pharmaco-medical products and treatments through enhancing stakeholder connectivity. Having transformed the business in the last 5 years, with two thirds of our earnings now derived from our international growth divisions – Commercial & Clinical and Product Access, the Group is poised to become a truly global provider of integrated solutions with a strong focus on speciality pharmaceuticals and innovative medtech portfolios while maintaining our leading Supply Chain & Retail position in the Irish market. I am especially proud of what Uniphar has achieved and the team and culture we have created, and we are excited by the global growth opportunity that lies ahead for the business.”